GISAID

GISAID, originally meaning the Global Initiative on Sharing Avian Influenza Data and later expanded to the Global Initiative on Sharing All Influenza Data, is an international scientific data-sharing initiative established in 2008. It was created in response to concerns that conventional arrangements for exchanging influenza samples and sequence information did not adequately protect researchers and countries that generated the data. In particular, scientists and public-health authorities in developing countries were concerned that biological materials and genomic information could be shared internationally, used by commercial organizations, and converted into patented products without sufficient recognition, benefit sharing, or involvement of the original contributors. The initiative emerged from debates surrounding highly pathogenic H5N1 avian influenza. Italian researcher Ilaria Capua publicly advocated wider release of H5N1 sequence information in 2006, while Peter Bogner helped organize and finance the proposed platform. The GISAID name was introduced in a 2006 Nature correspondence supported by a large group of scientists. The platform was formally launched in Geneva in May 2008 during the 61st World Health Assembly. Unlike fully public sequence archives, GISAID uses user registration, identity verification, and a database access agreement. Its rules require users to credit data generators and restrict redistribution of downloaded data, while encouraging cooperation with the laboratories and countries that produced the sequences. GISAID became an important channel for genomic surveillance during the 2009 H1N1 pandemic and the 2013 H7N9 outbreak. Its role expanded dramatically during the COVID-19 pandemic. Early SARS-CoV-2 sequences were shared through the platform in January 2020, and laboratories around the world subsequently deposited millions of coronavirus genomes. These data supported variant detection, phylogenetic analysis, genomic epidemiology, public-health surveillance, and the development of tools used to monitor the international spread of SARS-CoV-2. The rapid sharing of the Omicron sequence from southern Africa in 2021 illustrated how the platform could help identify genetically related cases across countries. The database later broadened beyond influenza and SARS-CoV-2. In 2022, GISAID added mpox and respiratory syncytial virus data, reflecting a wider pathogen-surveillance ambition. Indonesia announced the creation of GISAID Academy in Bali in 2023 to support bioinformatics education and regional genomic-surveillance capacity. GISAID presents its model as open access in the sense that qualified users can obtain and analyze the data, but it is not equivalent to unrestricted public-domain repositories such as GenBank or the International Nucleotide Sequence Database Collaboration archives. Researchers must accept the platform's terms, and redistribution is limited. Supporters argue that these conditions protect contributors, encourage data sharing, and reduce fears of appropriation or premature publication. Critics argue that the restrictions, opaque access decisions, and inability to freely republish sequences impede independent verification and collaboration. The initiative faced significant governance and access criticism in 2023, when some researchers temporarily lost access and raw information relevant to debates about the origins of SARS-CoV-2 became unavailable. GISAID said that records had not been deleted and that visibility changes were connected to updates or corrections. Critics nevertheless questioned the consistency of access procedures and the concentration of operational authority. GISAID remains a major international repository for pathogen genomic information, although its governance, licensing model, and relationship with fully open databases continue to be debated.

GISAID developed from disputes over how influenza samples and genome sequences should be exchanged internationally. Since the establishment of the WHO's Global Influenza Surveillance and Response System in 1952, national influenza centers had supplied samples and information through international public-health channels. Critics argued that conventional arrangements could leave countries and laboratories with insufficient control over how their material was used, including by commercial vaccine developers. The immediate intellectual origin of GISAID was the H5N1 avian-influenza debate. In 2006, Ilaria Capua called for the rapid release of avian-influenza sequence information rather than keeping it in restricted systems. Peter Bogner responded to the proposal and helped develop the initiative's organizational and financial foundation. A Nature correspondence later introduced the GISAID acronym and described a proposed framework under which researchers would make sequence information available while retaining recognition and safeguards. The proposal attracted support from numerous prominent scientists and was initially associated with Cambia and the Creative Commons Science Commons project. Indonesia's reluctance in 2006 to continue sending avian-influenza samples through the existing system highlighted the political sensitivity of data ownership and benefit sharing. The country subsequently agreed to share data through GISAID, viewing the platform as a more balanced mechanism. In 2007, GISAID and the Swiss Institute of Bioinformatics announced cooperation under which the institute would build and administer the EpiFlu database. The relationship later ended in a contract dispute, and the database was disconnected from the GISAID portal in 2009, leading to litigation. GISAID formally launched in May 2008 in Geneva during the 61st World Health Assembly. In 2010, Germany announced a cooperation agreement to provide long-term hosting and technical infrastructure, with the Friedrich Loeffler Institute expected to support scientific plausibility checks and curation. By 2013, a Washington-based nonprofit associated with GISAID had been dissolved and operations were conducted through the German association Freunde von GISAID. The initiative proved useful during the 2009 H1N1 pandemic and the 2013 H7N9 outbreak. Its importance increased sharply during COVID-19. Chinese public-health researchers shared some of the earliest SARS-CoV-2 sequences through GISAID in January 2020. During the following years, the platform accumulated millions of coronavirus genomes from more than 170 countries. These submissions enabled laboratories and public-health agencies to identify emerging lineages, compare outbreaks, and follow the geographical spread of variants. GISAID's rapid handling of the sequence associated with Omicron helped investigators connect cases reported in different countries. In 2022, the database expanded to mpox and respiratory syncytial virus. Indonesia announced GISAID Academy in 2023, linking the initiative to training and regional surveillance capacity. The platform's contributor-recognition model has been proposed as a possible template for future international data-sharing systems. GISAID's controlled-access structure has always distinguished it from unrestricted repositories. Users must verify their identities and accept terms that prohibit unauthorized redistribution and require attribution to data generators. The approach is intended to address concerns that sequence data could be used without credit, lead to premature publication, or support intellectual-property claims that disadvantage countries supplying samples. However, researchers have also argued that the rules limit reproducibility and make it difficult to transfer data into open archives. Governance tensions became especially visible in 2023. Some researchers lost access to the database, and data relevant to investigations into the early origins of SARS-CoV-2 temporarily became unavailable. GISAID said records were not deleted and that changes reflected maintenance or correction procedures, but critics described access decisions as confusing and arbitrary. Funding organizations and scientific observers also questioned the transparency of the initiative's management and the concentration of authority around its leadership. These disputes weakened the platform's claim to unrestricted openness, while its scientific value as a large contributor-based genomic repository remained widely recognized.

• 2023

  GISAID Academy is announced

  [1]GISAIDen.wikipedia.org

  Indonesia announces a Bali-based academy focused on bioinformatics training and genomic-surveillance capacity.

• 2022

  Pathogen coverage broadens

  [1]GISAIDen.wikipedia.org

  Mpox and respiratory syncytial virus are added to the supported pathogen datasets.

• 2020

  SARS-CoV-2 data-sharing expands rapidly

  [1]GISAIDen.wikipedia.org

  GISAID becomes a principal international repository for coronavirus genome sequences during the COVID-19 pandemic.

• 2013

  Operations move to a German association

  [1]GISAIDen.wikipedia.org

  Freunde von GISAID becomes the organizational vehicle for the initiative after dissolution of a Washington nonprofit.

• 2010

  Germany becomes long-term host

  [1]GISAIDen.wikipedia.org

  Germany announces support for hosting and maintaining the platform and for scientific data curation.

• 2008

  GISAID formally launches

  [1]GISAIDen.wikipedia.org

  The initiative launches in Geneva at the 61st World Health Assembly as a registration-based database.

• 2007

  EpiFlu cooperation announced

  [1]GISAIDen.wikipedia.org

  GISAID and the Swiss Institute of Bioinformatics agree to develop and administer an influenza sequence database.

• 2006

  H5N1 data-sharing proposal emerges

  [1]GISAIDen.wikipedia.org

  Ilaria Capua and other scientists advocate broader sharing of avian-influenza genomic data, providing the conceptual foundation for GISAID.

A contributor-protective, internationally coordinated alternative to unrestricted public sequence archives, designed to accelerate real-time pathogen surveillance while recognizing the laboratories and countries that generate genomic data.

• Influenza genomic database · 2008

  EpiFlu

  GISAID's original influenza-focused database, created to support the exchange and analysis of influenza virus sequence information while preserving attribution and participation rights for contributing laboratories and countries.

• Coronavirus genomic database · 2020

  EpiCoV

  The SARS-CoV-2 data environment associated with GISAID. It became a major source of coronavirus genome submissions during COVID-19 and supports lineage, variant, and genomic-epidemiology analysis by registered users.

• Pathogen genomic data platform · 2008

  GISAID pathogen surveillance platform

  The broader GISAID platform supports genomic information for multiple pathogens, including influenza viruses, SARS-CoV-2, mpox virus, and respiratory syncytial virus. Its model combines database access controls, contributor attribution, and international surveillance use.

• Bioinformatics education · 2023

  GISAID Academy

  An education and capacity-building initiative announced in Indonesia, intended to improve bioinformatics skills, pathogen genomic surveillance, and regional outbreak-response capabilities.

• 2023

  Access suspensions and governance criticism

  Researchers criticized GISAID after some accounts were suspended and data relevant to SARS-CoV-2 origin investigations temporarily became inaccessible. Critics also questioned the transparency and consistency of the platform's governance and access rules.

  Source

• 2009

  EpiFlu database contract dispute

  The Swiss Institute of Bioinformatics disconnected the database from the GISAID portal after a contract dispute, resulting in litigation.

  Source

Read more

• 2023GISAID Academy

  Indonesia · Asia-Pacific

  Indonesia announced an academy in Bali intended to provide bioinformatics education and strengthen regional genomic-surveillance capacity.

  Outcome. The announcement extended GISAID's role from data hosting toward technical training and workforce development.

  Source
• 2020Global SARS-CoV-2 genomic surveillance

  Global

  GISAID coordinated the collection and controlled sharing of SARS-CoV-2 genome sequences from laboratories worldwide during the COVID-19 pandemic.

  Outcome. The platform became one of the principal international resources for tracking viral variants and transmission patterns.

  Source

• 2023

  Propose stronger governance processesStrategy

  Background

  Criticism of access decisions and organizational transparency increased after researchers were suspended or temporarily unable to view certain data.

  Action taken

  GISAID leadership reportedly discussed an independent compliance board and new processes for handling governance and scientific disputes.

  Aftermath

  The proposals did not eliminate public criticism over access restrictions and the initiative's management structure.

  Source

• 2022

  Add mpox and RSV datasetsProduct launch

  Background

  GISAID sought to broaden its relevance beyond influenza and COVID-19 surveillance.

  Action taken

  The platform added mpox virus and respiratory syncytial virus to its supported pathogen coverage.

  Aftermath

  The expansion positioned GISAID as a broader pathogen-genomics initiative rather than a database focused only on influenza and SARS-CoV-2.

  Source

• 2020

  Expand the platform to SARS-CoV-2Product launch

  Background

  The COVID-19 pandemic created an urgent need for rapid international exchange of coronavirus genome sequences.

  Action taken

  GISAID accepted and disseminated SARS-CoV-2 genomic submissions through its controlled-access platform.

  Aftermath

  The database became a central resource for monitoring variants and conducting genomic epidemiology worldwide.

  Source

• 2008

  Adopt a controlled-access sharing modelStrategy

  Background

  GISAID was created amid concerns that unrestricted or conventional sharing arrangements could expose contributors to loss of credit, premature publication, or unwanted intellectual-property claims.

  Action taken

  The initiative required registration and acceptance of a database access agreement rather than placing all records in an unrestricted public archive.

  Aftermath

  The model encouraged participation by many data-generating laboratories but later drew criticism because users could not freely redistribute the data.

  Source

1. 1GISAIDen.wikipedia.org
2. 2GISAID official websitegisaid.org